Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute
- PMID: 17544323
- DOI: 10.1016/j.sleep.2007.03.022
Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute
Erratum in
- Sleep Med. 2007 Nov;8(7-8):788. Earley, Christopher J [added]
Abstract
Objectives: Augmentation of symptom severity is the main complication of dopaminergic treatment of restless legs syndrome (RLS). The current article reports on the considerations of augmentation that were made during a European Restless Legs Syndrome Study Group (EURLSSG)-sponsored Consensus Conference in April 2006 at the Max Planck Institute (MPI) in Munich, Germany, the conclusions of which were endorsed by the International RLS Study Group (IRLSSG) and the World Association of Sleep Medicine (WASM). The Consensus Conference sought to develop a better understanding of augmentation and generate a better operational definition for its clinical identification.
Design and methods: Current concepts of the pathophysiology, clinical features, and therapy of RLS augmentation were evaluated by subgroups who presented a summary of their findings for general consideration and discussion. Recent data indicating sensitivity and specificity of augmentation features for identification of augmentation were also evaluated. The diagnostic criteria of augmentation developed at the National Institutes of Health (NIH) conference in 2002 were reviewed in light of current data and theoretical understanding of augmentation. The diagnostic value and criteria for each of the accepted features of augmentation were considered by the group. A consensus was then developed for a revised statement of the diagnostic criteria for augmentation.
Results: Five major diagnostic features of augmentation were identified: usual time of RLS symptom onset each day, number of body parts with RLS symptoms, latency to symptoms at rest, severity of the symptoms when they occur, and effects of dopaminergic medication on symptoms. The quantitative data available relating the time of RLS onset and the presence of other features indicated optimal augmentation criteria of either a 4-h advance in usual starting time for RLS symptoms or a combination of the occurrence of other features. A paradoxical response to changes in medication dose also indicates augmentation. Clinical significance of augmentation is defined.
Conclusion: The Consensus Conference agreed upon new operational criteria for the clinical diagnosis of RLS augmentation: the MPI diagnostic criteria for augmentation. Areas needing further consideration for validating these criteria and for understanding the underlying biology of RLS augmentation are indicated.
Similar articles
-
Restless legs syndrome in end-stage renal disease.Sleep Med. 2004 May;5(3):309-15. doi: 10.1016/j.sleep.2004.01.014. Sleep Med. 2004. PMID: 15165541 Review.
-
The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.Sleep Med. 2009 Jun;10(6):611-5. doi: 10.1016/j.sleep.2008.09.007. Epub 2009 Feb 5. Sleep Med. 2009. PMID: 19200780
-
Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI).Sleep Med. 2009 May;10(5):515-23. doi: 10.1016/j.sleep.2008.06.006. Epub 2008 Sep 26. Sleep Med. 2009. PMID: 18823819
-
Augmentation as a treatment complication of restless legs syndrome: concept and management.Mov Disord. 2007;22 Suppl 18:S476-84. doi: 10.1002/mds.21610. Mov Disord. 2007. PMID: 17580331 Review.
-
Empirical evaluation of the accuracy of diagnostic criteria for Restless Legs Syndrome.Sleep Med. 2009 May;10(5):524-30. doi: 10.1016/j.sleep.2008.06.007. Epub 2008 Nov 8. Sleep Med. 2009. PMID: 18996741
Cited by
-
Restless legs syndrome variants: A systematic review.Heliyon. 2024 Mar 27;10(7):e28896. doi: 10.1016/j.heliyon.2024.e28896. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38596027 Free PMC article.
-
Spinal cord stimulation in severe pharmacoresistant restless legs syndrome-two case reports.Front Neurol. 2023 Nov 30;14:1219881. doi: 10.3389/fneur.2023.1219881. eCollection 2023. Front Neurol. 2023. PMID: 38099065 Free PMC article.
-
Adjunctive tonic motor activation enables opioid reduction for refractory restless legs syndrome: a prospective, open-label, single-arm clinical trial.BMC Neurol. 2023 Nov 21;23(1):415. doi: 10.1186/s12883-023-03462-6. BMC Neurol. 2023. PMID: 37990163 Free PMC article. Clinical Trial.
-
Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry.Neurology. 2023 Apr 4;100(14):e1520-e1528. doi: 10.1212/WNL.0000000000206855. Epub 2023 Jan 25. Neurology. 2023. PMID: 36697248 Free PMC article.
-
Peripheral Iron Metabolism is Associated with Leg Movements on Polysomnography but Not with the Severity of Restless Legs Syndrome or Its Impact on Patients.Nat Sci Sleep. 2022 Oct 13;14:1829-1842. doi: 10.2147/NSS.S378970. eCollection 2022. Nat Sci Sleep. 2022. PMID: 36263372 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous